Department of Urology, University of California, San Diego Health System2Urologic Cancer Unit, University of California, San Diego Moores Cancer Center, La Jolla3Section of Surgery, VA San Diego Healthcare System, San Diego, California.
Division of Biostatistics, University of California, San Diego Moores Cancer Center, La Jolla5Department of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla.
JAMA Surg. 2014 Aug;149(8):845-51. doi: 10.1001/jamasurg.2014.31.
Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error.
To investigate associations of patient safety with the diffusion of minimally invasive radical prostatectomy (MIRP) resulting from the development of the da Vinci robot.
DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 401 325 patients in the Nationwide Inpatient Sample who underwent radical prostatectomy during MIRP diffusion between January 1, 2003, and December 31, 2009.
We used Agency for Healthcare Research and Quality Patient Safety Indicators (PSIs), which measure processes of care and surgical provider performance. We estimated the prevalence of MIRP among all prostatectomies and compared PSI incidence between MIRP and open radical prostatectomy in each year during the study. We also collected estimates of MIRP incidence attributed to the manufacturer of the da Vinci robot.
Patients who underwent MIRP were more likely to be white (P = .004), have fewer comorbidities (P = .02), and have undergone surgery in higher-income areas (P = .005). The incidence of MIRP was substantially lower than da Vinci manufacturer estimates. Rapid diffusion onset occurred in 2006, when MIRP accounted for 10.4% (95% CI, 10.2-10.7) of all radical prostatectomies in the United States. In 2005, MIRP was associated with an increased adjusted risk for any PSI (adjusted odds ratio, 2.0; 95% CI, 1.1-3.7; P = .02) vs open radical prostatectomy. Stratification by hospital status demonstrated similar patterns: rapid diffusion onset among teaching hospitals occurred in 2006 (11.7%; 95% CI, 11.3-12.0), with an increased risk for PSI for MIRP in 2005 (adjusted odds ratio, 2.7; 95% CI, 1.4-5.3; P = .004), and onset among nonteaching hospitals occurred in 2008 (27.1%; 95% CI, 26.6-27.7), with an increased but nonsignificant risk for PSI in 2007 (adjusted odds ratio, 2.0; 95% CI, 0.8-5.2; P = .14).
During its initial national diffusion, MIRP was associated with diminished perioperative patient safety. To promote safety and protect patients, the processes by which surgical innovations disseminate into clinical practice require refinement.
在没有协调系统来确保手术创新安全融入临床实践的情况下,手术创新会传播,这可能会使患者面临更高的医疗错误风险。
研究达芬奇机器人发展导致的微创根治性前列腺切除术(MIRP)传播与患者安全之间的关联。
设计、地点和参与者:对 2003 年 1 月 1 日至 2009 年 12 月 31 日期间接受 MIRP 期间的全国住院患者样本中 401325 名接受根治性前列腺切除术的患者进行了队列研究。
我们使用了医疗保健研究和质量患者安全指标(PSIs),这些指标衡量了护理过程和外科医生的表现。我们估计了所有前列腺切除术患者中 MIRP 的流行率,并在研究期间的每年比较了 MIRP 和开放式根治性前列腺切除术之间的 PSI 发生率。我们还收集了归因于达芬奇机器人制造商的 MIRP 发病率的估计。
接受 MIRP 的患者更可能是白人(P = .004),合并症较少(P = .02),并且在高收入地区接受手术(P = .005)。MIRP 的发病率远低于达芬奇制造商的估计。快速扩散始于 2006 年,当时 MIRP 占美国所有根治性前列腺切除术的 10.4%(95%CI,10.2-10.7)。2005 年,MIRP 与任何 PSI 的调整后风险增加相关(调整后的优势比,2.0;95%CI,1.1-3.7;P = .02),而与开放式根治性前列腺切除术相比。按医院状况分层显示出类似的模式:教学医院的快速扩散始于 2006 年(11.7%;95%CI,11.3-12.0),MIRP 的 PSI 风险增加,2005 年(调整后的优势比,2.7;95%CI,1.4-5.3;P = .004),而非教学医院的快速扩散始于 2008 年(27.1%;95%CI,26.6-27.7),2007 年 PSI 风险增加但无统计学意义(调整后的优势比,2.0;95%CI,0.8-5.2;P = .14)。
在最初的全国传播过程中,MIRP 与围手术期患者安全性降低有关。为了促进安全性并保护患者,需要改进手术创新传播到临床实践的过程。